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SUMMARY 
 Cryptolepis sanguinolenta (Lindl.) Schltr 
(Periplocaceae), has a longstanding traditional use in 
the treatment of malaria in the West African region. 
Recent evidence suggests that the aqueous extract from 
the roots and the major alkaloid from the plant, 
cryptolepine, have prospects as cancer 
chemotherapeutic agents on account of their potent 
cytotoxicity to mammalian cells. Several mechanisms 
have been proposed to explain the cytotoxic activities 
of the agents. However, emerging evidence from their 
anti-inflammatory actions suggest that the mechanism 
of the cytotoxicity may be closely related to its anti-
inflammatory activity. This review looks at the 
mechanisms of cryptolepis-induced cytotoxicity, its 
link with inflammation and its potential as anticancer 
agent. The elucidation of these interwoven mechanisms 
may be useful in the development of cryptolepine or 
other analogues as new anticancer agents. 
  
INTRODUCTION 
Cryptolepis sanguinolenta (Lindl.) Schltr 
(Periplocaceae) is a popular Central and West African 
anti-malarial plant that has attracted scientific research 
for the past four decades. Its numerous biological 
effects1,2,3 have been attributed to its main alkaloid, 
cryptolepine (Figure 1). Recently, cryptolepine has 






Figure 1  Cryptolepine, the main alkaloid from the 
aqueous root extract of Cryptolepis sanguinolenta. 
 
The worldwide increase in cancer incidence, reported 
treatment failures and the side effects associated with 
most of the conventional anticancer medications call 
for further research and exploration for newer agents 
for cancer management. Several studies with 
cryptolepis and its major alkaloid show very potent 
cytotoxic activity4,5,7 and multiple mechanisms of 
action have been suggested.  Recent emerging evidence 
also suggests that the mechanism of the cytotoxicity 
may be closely related to its anti-inflammatory actions.  
 
This paper examines the interwoven mechanisms 
involved in the cytotoxicity and anti-inflammatory 
activity of cryptolepis and its alkaloid, cryptolepine, 
and suggests possible roles that cryptolepis and 
cryptolepine could play in the management of certain 
forms of cancer. 
 
Cytotoxicity of Cryptolepis and Cryptolepine  
Prior to the discovery of cryptolepis’s cytotoxicity 
against several mammalian cancer cell lines in vitro4 its 
main alkaloid, cryptolepine, was empirically believed 
to have the potential to interact with DNA due to its 
apparent structural similarity to 9-aminoacridine, 
which intercalates DNA.8 Subsequently, it was shown 
to bind to DNA and inhibit DNA synthesis.9 At the turn 
of the 21st century, cryptolepine and its structural 
analogues were known to have DNA and 
topoisomerase II as their principal targets.10  
 
Cryptolepine was first shown as cytotoxic due to its 
reported interference with the nuclear ubiquitous 
enzyme topoisomerase II.10 Topoisomerase II 
inhibition is a major mechanism of several anticancer 
agents including etoposide to induce apoptosis.11 
However, cells treated with cryptolepine in vitro have 
very low survival rates.4 This report together with the 
fact that cryptolepine unlike other topoisomerase II 
inhibitors had low mutagenicity12,13 suggested  that 
topoisomerase II inhibition may not wholly account for 
the cytotoxic action of cryptolepine.   
 
 




Indeed in cell cultures, cryptolepine showed G1 and 
sub-G1 peaks characteristic of apoptotic cell 
population.4,5  
 
It has already been proposed that p53 may be involved 
in the cellular response to DNA damage, producing 
arrest in the G1 phase of the cell cycle to allow 
efficient repair of DNA before entry to S phase, or cell 
death if the damage is too overwhelming to be 
repaired.14,15 The work by Zhu and Gooderham, 
(2006)5 in human lung adenocarcinoma A549 cells 
lines showed that cryptolepine provokes p53 
accumulation at all concentrations. At the molecular 
level, cryptolepine has a unique planar structure 
allowing it to slide into DNA and intercalating it 
particularly at CG rich regions and non-alternating CC 
sites.9 Furthermore, accumulation of DNA strand 
breaks is a well-known stimulus for elevating p53 
protein levels and for activating p53-mediated 
signaling pathways.16,17 
 
 This alteration in DNA structure and function lead to 
activation of p53 and subsequently its transcriptional 
targets such as p21.18  Cryptolepis treatment inhibits 
Bcl-2, a protooncogene blocking apoptotic cell death, 
and causes the release of cytochrome C into the 
cytosol.4,5 The overall executioner of apoptosis is 
caspase19 and cryptolepine efficiently promotes the 
activation of caspase-3 but has a modest effect on 
caspase 8, suggesting a mode of apoptotic cell death 
executed at least in part through the mitochondrial 
pathway.4,5 
 
Pathophysiology of Cancer and the link with 
Inflammation 
It has been shown that inflammation is closely linked 
to tumour promotion and nearly all tumors have 
inflammatory cells present in them irrespective of the 
underlying cause of the tumor.20 Inflammation can alter 
the expression of oncogenes and tumor suppressor 
genes, induce genomic instability, increase 
angiogenesis, alter the genomic epigenetic state and 
increase cell proliferation to promote neoplastic 
transformation.21 Carcinogenesis affects the expression 
of various inflammatory genes and leads to recruitment 
of inflammatory cells. Evidence from several studies 
demonstrates that certain anti-inflammatory drugs 
(NSAIDS) have been associated with reduced risk of 
several different types of cancer suggesting a link 
between inflammation and cancer.22  
  
Molecular mediators common to inflammation and 
cancer 
Several molecular pathways connect chronic 
inflammation with oncogenic transformation. Common 
inflammatory mediators including cytokines, 
chemokines, reactive oxygen and nitrogen species, 
COX-2 and NF-kB can lead to cellular conditions 
favorable for tumor promotion. 
 
Cyclooxygenase-2 (COX-2) 
Prostaglandins (PGs), the main products of COX 2 
activity affect cell proliferation, mitosis, cell adhesion, 
apoptosis and immune surveillance. Over-expression 
and up-regulation of COX-2 have been found in 
cancers of the breast, colon, lung, pancreas, head and 
neck cancers in humans.23,24,25 different types of 
tumours and transformed cells.26,27,28  COX-2 prolongs 
the survival of malignant or transformed cells, elevates 
Bcl-2 protein expression (anti-apoptotic factor) and 
diminishes levels of transforming growth factor beta-2 
(TGFβ-2) receptor and E-cadherin.25 
 
Inducible nitric oxide synthase 
Inducible nitric oxide synthase (iNOS) is one enzyme 
that works synergistically with COX-2. Up-regulation 
of COX-2 and iNOS has been associated with 
pathophysiology of certain types of human cancers. 
iNOS catalyzes the oxidative deamination of L-
arginine to produce NO, a potent pro-inflammatory 
mediator. NO has multiple roles in mutagenesis and 
carcinogenesis.29,30,31,32,33 This is evident by the 
observation that inhibition of NO release cause 
profound suppression of PG production.34 Over-
production of reactive oxygen and nitrogen species 
(RONS), aberrant inflammatory cytokine and 
chemokine expression, increased COX-2 and nuclear 
factor kappa B (NF-kB) expression are some of the 
molecular factors that contribute to inflammation-
induced carcinogenesis. 
  
Nuclear Factor kappa Beta (NF-kB) 
NF-kB is a transcription factor and a key mediator of 
inflammation-induced carcinogenesis. NF-kB has a 
variety of pro-tumorigenic activities. Under normal 
cellular conditions, NF-kB binds to and is negatively 
regulated by inhibitor of kappa B (ikb) in the 
cytoplasm. The NF-kB can be detected in its inactive 
form in the cytoplasm of almost all cell types.35,36 
Following an inflammatory episode, inhibitor of kappa 
B is phosphorylated and undergoes proteosomal 
degradation. This allows an activated NF-kB to 
translocate to the nucleus where it activates the 
transcription of target genes. NF-kB appears to be the 
endogenous link that induces expression of COX-2, 
TNFa and iNOS.37,38,39,40  
 
Although experimental data clearly suggest that NF-kB 
is a major regulator of the inflammatory reaction by 
controlling the expression of pro-inflammatory 
molecules in response to cytokines, oxidative stress 
and infectious agents41,42, NF-kB also regulates genes 
 
 




including c-Jun-N-terminal kinase, inhibitors of 
apoptosis proteins 1 and 2, TNF receptor-associated 
factors 1 and 2, protein 53 (p53), B-cell CLL/ 
lymphoma 2, chemokine (C-X-C motif) receptor 4, 
vascular endothelial growth factor and angiopoetin, 
leading to pro-tumorigenic angiogenesis, metastasis 
and increased cell resistance to necrosis and 
apoptosis.21,43 
 
Cryptolepis/Cryptolepine as potent anti-
inflammatory agents  
Cryptolepis is used traditionally to manage fevers and 
other febrile conditions. Bamgbose and Noamesi44 
reported the potent anti-inflammatory activity of 
cryptolepine, the major alkaloid of cryptolepis. The 
study reported on the ability of cryptolepine to directly 
antagonize the actions PGE2 without affecting 
prostaglandin synthesis in the perfused lung of the 
rainbow lizard. At the time of the study, very little was 
known about the isoenzymes of COX but the study 
well established that the mechanism of the anti-
inflammatory activity of cryptolepine may be slightly 
different from that of conventional NSAIDS. 
 
Subsequently, Olajide et al., had argued that the anti-
inflammatory activity of cryptolepis and cryptolepine 
was due to inhibition of COX-2 and hence its apparent 
low ulcerogenic activity in rats.45,46,47,48  Together, the 
above findings are in agreement that 
cryptolepis/cryptolepine inhibits prostaglandin E2 
activity. In addition, other key promoters of 
inflammation such iNOS and NF-kB were all affected 
by cryptolepine. 
 
Is the cytotoxic action of cryptolepis/cryptolepine 
linked with its anti-inflammatory activity? 
Substances with potent anti-inflammatory activity 
inhibit carcinogenesis and mutagenesis.49,50 This has 
been shown for several anti-inflammatory agents. 
Inhibition of COX-2 activity is thought to be one of the 
mechanisms by which NSAIDs exert their 
antineoplastic effects.51,52 More than 85% of human 
cancers have increased levels of COX-2 when 
compared with adjacent normal tissue.53,54 
Cryptolepine exhibits potent cytotoxicity and potent 
anti-inflammatory activity.45,46,47,48  Protein 53 (p53) 
and NF-kB are key mediators of both processes.  
 
Protein 53 is the cellular gate keeper of cytotoxicity. 
The p53 protein is up-regulated in response to a diverse 
array of cellular stresses, including DNA damage, 
hypoxia, oxidative stress, ribonucleotide depletion, and 
oncogene activation.55,56 This tumour suppressor 
protein inhibits cell growth through activation of cell-
cycle arrest and apoptosis and more than half of all 
human tumours have either mutation within the p53 
gene or defects in the ability to induce p53.  
 
NF-kB is a major regulator of the inflammatory 
reaction by controlling the expression of pro-
inflammatory molecules in response to cytokines, 
oxidatives stress and infectious agents.41,57 Pro-
inflammatory mediators promote tumourigenesis and 
carcinogenesis. NF-kB acts as anti-apoptotic by 
inducing the expression of the inhibitors of 
apoptosis58,59,60 and some members of the anti-apoptotic 
Bcl-2 family61,62 which also antagonize the function of 
the pro-apoptotic members including A1/BFL1 and 
Bcl-XL of the family, and subsequently suppress 
apoptosis induced by both extrinsic and intrinsic 
pathways through direct inhibition of effector caspases 
(caspases-3, -6, -7, and 9). 
 
In transformed cells, molecular alterations result in 
impaired regulation of NF-κB activation leading to loss 
of its inducibility and activation constitutively. This 
leads to deregulated expression of genes under NF-κB 
control. Among them are genes involved in regulation 
of apoptosis, cell cycle control, adhesion or migration. 
Since alterations in all these processes participate in 
development and progression of cancer, there is a clear 
link between NF-κB and carcinogenesis. 
 
NF-kB has pro-apoptotic activity as well. Other reports 
indicate that induction of NF-kB is also associated with 
growth arrest and cellular differentiation.63,64,65 In 
particular, NF-kB stimulates the tumor suppressor gene 
p5363, which is key to apoptotic cell death. The dual 
role of NF-kB in cell survival and cell death may be 
due to several reasons and mechanisms as well as the 
structure and function of NF-kB. The mammalian NF-
kB transcription factor family is not a single gene but a 
family of closely related genes producing five proteins 
of two subfamilies: Rel subfamily, (Rel B, p65 (Rel A), 
and c-Rel)42,66 which contain C-terminal transactivation 
and p50 and p52 proteins, which lack transactivating 
C-terminal region domains.42,66 The different NF-kB 
family members can form hetero- or homodimers to 
produce 15 possible NF-kB transcription factor 
complexes Hetero- or homo-dimers containing Rel 
proteins are activators of transcription whilst 
homodimers of p50 or p52 act as repressors of gene 
transcription.42,66 This explains why NF-kB acts as 
activator or repressor of transcription in normal cells. 
 
 Inhibition of NF-kB activity and up-regulation of 
p53 is responsible for anti-inflammatory and 
cytotoxicity of cryptolepis/cryptolepine 
Current trends suggest that the interplay between NF-
kB and p53 determine cell survival and cell death.  
 
 




Under normal conditions in cells, Hdm2 inhibits p53-
induced apoptosis. The Hdm2 promoter contains an 
NF-kB binding site. This process prevents p53 from 
triggering apoptosis. Aberrant expression and 
activation of NF-kB suppress the activation of p53 
thereby inhibiting the induction of p53 target genes and 
DNA damage-induced apoptosis leading to increase 
cell survival and resistance to apoptosis.67 Once the 
activity of NF-kB has been reduced, Hdm2 inhibition 
of p53 is attenuated and the cell proceeds through a 
p53-mediated apoptotic pathway. This leads to the 
inhibition of the expression of inflammatory genes and 
consequent reduction in tumor incidence.  
 
Cryptolepine as inhibitor of NF-kB activity and an 
inducer of p53 
Cryptolepine inhibits the activity of NF-kB.46 The 
interaction of cryptolepine  with NF-kB may be 
different from other conventional anti-inflammatory 
agents, which act by inhibiting IKK. Cryptolepine acts 
downstream by interfering with the DNA binding 
capacity of NF-kB and inhibiting NF-kB-mediated 
gene expression.45 This impairs the initiation of 
transcription of not only pro-inflammatory proteins, but 
also regulators of the NF-kB pathway such as IkB. 
Cryptolepine does not interfere with phosphorylation 
and degradation of IkB or the nuclear entry of NF-kB. 
Evidence supporting this pathway is that, substances 
with thiol groups such as DTT are able to reduce the 
effects of cryptolepine on NF-kB as they compete with 
cryptolepine for CC sites of DNA reducing 
intercalation.46 
 
The cytotoxicity of cryptolepine is likely to be 
mediated by activation of p53 as genes that activate 
cryptolepine induced-cell death are regulated by 
expression of p53.4,5 The key to effective cancer 
therapy is activation or re-introduction of p53 induced 
apoptosis in tumour cells. 
 
Cryptolepis/cryptolepine as candidate anticancer 
agents 
The potential of cryptolepine as an anticancer agent has 
never been disputed. Cryptolepine also posseses 
several advantages over mainstream anticancer agents. 
Preclinical studies with cryptolepine, the main alkaloid 
of cryptolepis, show that it has activity against several 
solid human tumours with breast tumours being the 
most sensitive.7 Cryptolepine, however showed 
differences in activity in patient tumour samples in 
both solid tumours and haematological malignancies.7  
Interestingly, cisplatin a standard cytotoxic drug is 
known to exhibit that property. Perhaps the reason why 
cryptolepine shows prominent activity in breast 
tumours may be related to its ability to affect cyclins 
D1, D2, D3 and cyclin E, which control cell cycle 
progression, as NF-kB-induced cyclin D1 expression 
appears to be a key element in mammary gland 
development and breast carcinogenesis.68 
 
Cryptolepis/cryptolepine and prostatic disorders 
We recently observed in our laboratory that cryptolepis 
is potently antiandrogenic in rodents and aves. Its 
potency by our estimation is thirty times less than 
cyproterone acetate.69Androgens are required for the 
normal growth and development of the prostate and 
have been implicated in the pathogenesis of Benign 
Prostatic Hyperplasia (BPH).70 With its potent 
cytotoxicity, anti-inflammatory, anti-androgenic 
activity and its ability to antagonize NF-kB, we 
reasoned that cryptolepis/cryptolepine may be more 
effective in the management of androgen sensitive 
prostate cancers in men either as monotherapy or in 
combination with other anticancer agents.  
 
 Cryptolepis and cryptolepine may also be beneficial in 
other forms of prostate disorders particularly those that 
are non-androgen dependent. There is considerable 
experimental and epidemiological data suggesting the 
involvement of obesity, insulin resistance, 
hyperinsulinaemia, hyperlipidemia in the pathogenesis 
of Benign Prostatic Hyperplasia (BPH).71--74 Many risk 
factors for BPH such as insulin, insulin like growth 
factors (IGFs), and dyslipidaemia might act through 
androgen-independent mechanisms.75-78  
 
Insulin-resistance generally precedes Type 2 diabetes 
by 10 to 20 years79 and is associated with a group of 
disorders such as obesity, dyslipidemia, 
hyperglycaemia, hyperinsulinemia and hypertension. 
Recently it has been reported that the higher serum 
LDL is associated with greater risk of BPH 73 and 
might be one of the important risk factors in the 
pathogenesis of BPH.80 Report by Luo et al., 1998 81 
showed that cryptolepis/cryptolepine caused significant 
decrease in plasma glucose when given orally to a 
mouse model of diabetes. Traditionally, cryptolepis is 
used for such purposes. This reduction in glucose 
consequently leads to significant decline in plasma 
insulin concentration in hyperinsulinaemia. 
 
Cryptolepis/cryptolepine can interact with insulin and 
COX-2 in managing BPH. IGFs, especially IGF-II, are 
directly involved in tumorigenesis.82 IGF-II exerts its 
mitogenic activity through the insulin-like growth 
factor Type 1 IGF receptor (IGF-IR) 83 and activation 
of IGF-IR up-regulates phosphatidylinositol 3-
kinase/AKT-kinase (PI3k/AKT) signaling and 
increases proliferation and survival. Among 
mechanisms regulating IGF-IR expression, the 








COX-2 activates the Akt pathway through PGE2 in 
colon cancer cells 53, indicating that COX-2/PGE2 is 
involved in IGF-IR expression and subsequent 
inhibition leads to decrease in tumorigenesis. 
 
 Cryptolepis and resistance to chemotherapy. 
Resistance during chemotherapy is one of the main 
problems encountered in cancer treatment. This has led 
to the use of more than one anticancer agent for cancer 
management. This practice increases the side effects as 
well as the cost of chemotherapy. Laryea et al., (2009)7 
reported that cryptolepine was largely insensitive to 
established anti-cancer drug resistance mechanisms in 
preclinical studies. It has been hypothesized that 
tumors with constitutive NF-kB activation usually 
show increased resistance to chemotherapy and NF-kB 
may be responsible for blocking the efficacy of 
chemotherapy and radiation in some types of tumor 
cells.85  
 
 One of these target proteins is the FLICE-like 
inhibitory protein (FLIP) which shares a high degree of 
homology with caspase- 8 but lacks protease activity.  
FLIP competes with caspase-8 for the binding to the 
Death-Inducing Signaling Complex and FLIP 
expression may explain the resistance to death receptor 
apoptosis in some types of tumors.86-88It has been 
demonstrated that inhibition of NF-kB improves the 
apoptotic response to radiation therapy and 
chemotherapy.89  It has been suggested that NF-kB 
may induce the expression of the multidrug resistance 
P-glycoprotein. It is probable that the insensitivity of 
cryptolepine to established anti-cancer, antiplasmodial 
and antimicrobial mechanisms and  its  activity against 
chloroquin resistant falciparium7,90,91 is due to its 
effects on NF-kB and its interaction with multidrug 
resistance P-glycoprotein. This raises the possibility 
that cryptolepine may enhance sensitivity of cancer 
cells to chemotherapy and radiotherapy. 
 
 Low mutagenicity of cryptolepis/cryptolepine. 
Contrary to the mutagenic and genotoxic effects 
associated with many anticancer agents and cytotoxics, 
chronic cryptolepis usage may offer chemoprotection 
against the development of some cancers such as 
breast, prostate and colorectal cancers.  In in vivo and 
in vitro models, cryptolepis/cryptolepine exhibits low 
mutagenic potential.12,13 This appears to be closely 
linked to chemoprotective effects on carcinogenesis 
and mutagenesis exhibited by anti-inflammatory 
agents.49,50 Several mechanisms employed by mutagens 
are also targets for cryptolepis.  
 
It appears that the genesis of mutagenesis is alterations 
in essential DNA processes, which do not overwhelm 
the cell to cause death, but rather stimulate the 
initiation of repair of DNA aberrations in surviving 
populations 92-96. NF-kB upregulates genes such as 
COX-2, iNOS 97-101 and other non NF-kB targets such 
as topoisomerase II and the multiple pathways either 
singly or synergistically promote mutagenesis. 
Interestingly, cryptolepis/cryptolepine inhibits most of 
the pathways needed for neoplastic and metastatic 
transformation.  
 
Potential limitations of cryptolepis/cryptolepine as 
novel anticancer agents 
Despite its promising activity in preclinical and in vitro 
studies, cryptolepine has not left the confinement of the 
laboratory and has never entered any clinical study for 
assessment of its potential in cancer treatment. This 
may be related to the notion that anticancer agents that 
target DNA are relatively non-selective as both normal 
and tumour cells could be affected. There have been 
many structural modifications on the parent molecule 
in many laboratories to reduce its DNA intercalation 
and potential toxicity. It is thought that in some forms 
of cancers, local application and tumour targeted 
delivery of cryptolepine may be beneficial and may 
minimize systemic toxicity. 
 
In recent times, there has been considerable interest in 
the use of cryptolepis rather than cryptolepine. In our 
laboratory, a thin layer chromatogram of cryptolepis 
shows only cryptolepine as the major constituent 
suggesting that other components may be minor in 
relation to cryptolepine.69 Cryptolepis is used 
traditionally for the management of several diseases 
and has recently undergone a clinical study in Ghana as 
an antimalarial.102  It is relatively safe with its LD50 
estimated to be above 5000 mg/kg in rats.103  It is 
possible that other minor components may modulate 
the effects of cryptolepine in the aqueous extract and 
that property may be lost when cryptolepine is used as 
a pure compound. 
 
Potential effect of cryptolepis/cryptolepine on the 
renal system 
Cryptolepis/cryptolepine is anti-inflammatory and 
cytotoxic with the inhibition of COX-2 and NF-kB as 
principal mechanisms. We hypothesized that the 
kidneys could be a principal target for cryptolepine 
cytotoxicity as renal failure is a common complication 
of NSAIDs abuse104, 105 and cancer chemotherapy. 
 
In our laboratory, we noticed that cryptolepis at a dose 
beyond 100 mg/kg; p.o  progressively induced an 
apoptotic-like cell death in the kidneys of mice. 69 The 
process begins with condensation of groups of cells to 
form a multinucleated cell in tissues of the renal cortex 
and parts of the medullary regions. These cells pick up 
stain and appear dark, an indication of a condensation 
 
 




of their nuclear material. Many groups of cells undergo 
this process in the renal cortex but the surrounding 
tissues remain undisturbed. The bulk of the damage 
occurred in the renal cortex but major necrotic lesions 
were observed in the medulla.  
To the best of our knowledge, this is the first 
demonstration of apoptosis induced by aqueous 
Cryptolepis sanguinolenta in vivo.  
 
 
   
Figure 2 Induction of apoptotic-like cells in the renal cortex of mice treated with cryptolepis. (A) represents photomicrograph of 
the renal cortex of untreated mouse. (B) represents the renal cortex of mice after 14 days treatment with cryptolepis (100 mg/kg; 
p. o). Arrows show systematic renal damage by cryptolepis: condensation of groups of cells and renal lesions. (C) is a renal 
interstitium of mice showing a multinucleated cell after 14-day treatment with cryptolepis (100 mg/kg p.o)  
 
The reason for the present observation is that 
prostaglandins are essential for renal function. The 
kidney synthesizes prostaglandins from different 
locations, including afferent and efferent arteriole, 
glomeruli, and tubular system. It is highly possible 
that this effect of cryptolepis may be related to its 
inhibition of the activity of prostaglandins. COX-2 
null mice develop severe nephropathy.59,106 In 
humans, selective COX-2 inhibition causes sodium 
and water retention and transient decrease in 
glomerular filtration rate.104,107 
 
CONCLUSION 
Overall, this review has shown that the 
cytotoxicity and anti-inflammatory activity of 
cryptolepis/cryptolepine are closely linked and are 
likely to be mediated by interference with NF-kB 
activity leading to down-regulation of 
inflammatory and anti-apoptotic genes such COX- 
2, iNOS, TNFa, Bcl-2 and up-regulation of pro-
apoptotic genes such p53, p21, Bax, caspase and  
cytochrome C. Interference of NF-kB activity 
downstream by cryptolepis/cryptolepine may be 
exploited in cancer treatment or to enhance 
sensitivity of cancer cells to chemotherapy and 
radiotherapy. The properties of the agents clearly 
suggest that they have prospects as anticancer 
agents particularly in breast and prostate cancers.  
 
REFERENCES 
1. Boye, G.L., and Ampofo,O. Clinical uses of 
Cryptolepis sanguinolenta  (Asclepiadaceae).  
In, Boakye Yiadom, K., & Bamgbose S. O. A. 
(ed). Proceedings of the first International 
symposium on cryptolepine, 1983; Abstr 4. 
University of Science and Technology 
Kumasi Ghana. 
2. Bamgbose, S.O., and Noamesi, 
B.K.Preliminary report of some 
pharmacological actions of cryptolepine, 7th 
International Congress Pharmacology 
(Tokyo, Japan). 1978 Abstr 1289. 
3. Boakye –Yiadom, K.Antimicrobial properties 
of some west African medicinal plants II. 
Antimicrobial activity of aqueous extracts of 
Cryptolepis Sanguinolenta (Lindl.) Schlechter. 
QuartJ Crude Drug Res 1979;17: 78-80 
4. Ansah, C., and Gooderham, N.J. The Popular 
herbal, antimalarial, Extract of Cryptolepis is 
potentially cytotoxic. Toxicol 
Sci.2002;70:245-251. 
5. Zhu, H., and Gooderham, N.J. Mechanisms of 
Induction of Cell Cycle Arrest and Cell Death 
by Cryptolepine in Human Lung 
Adenocarcinoma A549 Cells. Toxicol Sci. 
2006;91: 132-139. 
6. Ansah, C., and Gooderham, N.J.Cryptolepine 
provokes changes in the expression of cell 
cycle proteins in growing cells. Am J 
Pharmacol Toxicol. 2009; 4: 177-185. 
7. Laryea, D., Isaksson, A., Wright, C.W., 
Larsson, R., and Nygren, P. Characterization 
of the cytotoxic activity of the indoloquinoline 
alkaloid cryptolepine in human tumour cell 
lines and primary cultures of tumour cells 
from patients. Invest New Drugs 2009;27: 
402–411. 
8. Wright, C.W., Phillipson, J.D., Awe, S.O., 
Kirby, G.C., Warhurst, D.C., Quertin-Leclerq, 
 
 
September 2013    Volume 47, Number 3  GHANA MEDICAL JOURNAL 
 143 
J., Angenot, L. Antimalarial activity of 
cryptolepine and some other anhydronium 
bases. Phytother Res 1996;10:361-363 
9. Lisgarten, J.N., Coll, M., Portugal, J., Wright, 
C.W., and Aymani, J. The anti-malarial and 
cytotoxic drug Cryptolepine intercalates into 
DNA at cytosine-cytosine sites. Nat Struct 
Biol 2001;9:57-60. 
10. Bonjean, K., De Pauw-Gillet, M.C., Defresne, 
M.C., Colson, P., Houssier, C., Dassonneville, 
L., Baily, C., Greimers, R., Wright, C., 
Quetin-Leclercq, J., et al. The DNA 
intercalating alkaloid cryptolepine interferes 
with topoisomerase II and inhibits primarily 
DNA synthesis in B16 melanoma cells. 
Biochemistry 1998; 37:5136-5146. 
11. Kluza, J., Lansiaux, A., Wattez, N., Mahieu, 
C., Osheroff, N., Bailly, C. Apoptotic 
Response of HL-60 Human Leukemia Cells to 
the Antitumor Drug TAS-103. Cancer 
Res.2000; 6: 4077 
12. Ansah, C., Khan, A., and Gooderham, N.J. In 
vitro genotoxicity of the West African anti-
malarial herbal Cryptolepis sanguinolenta and 
its major alkaloid cryptolepine. Toxicology; 
2005:208,141-147. 
13. Ansah, C., Mensah, K. B.  Woode, E. and 
Duweijua M. Reproductive and 
developmental toxicity of Cryptolepis 
sanguinolenta in mice. Res J Pharmacol 
2010;4(1):9-14. 
14. Li H.L., Zhang, H.W.,and Ren, X.D. 
Synergism between heparin and adriamycin 
on cell proliferation and apoptosis in human 
nasopharyngeal carcinoma CNE2 cells. Acta 
Pharmacol Sin 2002;23:167-172 
15. Li H.L., Ye, K.H.,and Ren, X.D. Heparin 
induced apoptosis in human nasopharyngeal 
carcinoma CNE2 cells. Cell Res 2002;11:311-
315 
16. Jayaraman, J. and Prives, C. Activation of p53 
sequence specific DNA binding by short 
single strands of DNA requires the p53 C-
terminus. Cell. 1995;81:1021–1029 
17. Huang, L.C., Clarkin, K..C., and Wahl, G.M. 
Sensitivity and selectivity of the DNA damage 
sensor responsible for activating p53-
dependent G1 arrest. Proc. Natl. Acad. Sci. 
U.S.A. 1996;93:4827–4832. 
18. Cox, S.L. Multiple pathways control cell 
growth and transformation: overlapping and 
independent activities of p53 and 
p21Cip1/WAF1/Sdi1. J Pathol 
1997;183:134–140 
19. Cohen, G.M. Caspases: the executioners of 
apoptosis. Biochem J 1997;326: 1-6 
20. Medzhitov, R.Origin and physiological roles 
of inflammation. Nature.2008;454:428–435. 
21. Schetter, A.J., Heegaard, H.H.N., and Harris 
C.C. Inflammation and cancer: interweaving 
microRNA, free radical, cytokine and p53 
pathways. Carcinogenesis 2010;31:37–49 
22.  Cuzick, J., Otto, F., Baron J.A., Brown, P.H., 
Burn, J., Greenwald, P.,Jankowski, J., La 
Vecchia, C.  Meyskens, F.,  Jörg Senn, H. 
Aspirin and non-steroidal anti-inflammatory 
drugs for cancer prevention: an international 
consensus statement. Lancet Oncol. 
2009;10:501–507. 
23. Goodwin, J.S., and Ceuppens, J. Regulation of 
immune response by prostaglandins. J Clin 
Immunol 1983;3:295–314. 
24. Qiao, L., Kozoni, V., Tsioulias, G.J., Koutsos, 
M.I., Hanif, R., Shiff, S.J., and Rigas, B. 
Selected eicosanoids increase the proliferation 
rate of human colon carcinoma cell lines and 
mouse colonocytes in vivo. Biochim Biophys 
Acta 1995;1258: 215–223. 
25. Tsujii, M., and DuBois, R.N. Alterations in 
cellular adhesion and apoptosis in epithelial 
cells overexpressing prostaglandin 
endoperoxide synthase 2. Cell 1995;83: 493–
501.  
26. Xie, W. and Herschman, H.R. v-src induces 
prostaglandin synthase-2 gene expression by 
activation of the c-Jun N-terminal kinase and 
c-Jun transcription factor. J Biol Chem 1995; 
270:27622–27628. 
27. DuBois, R.N., Radhika, A., Reddy, B.S., and 
Entingh, A.J. Increased cyclooxygenase-2 
levels in carcinogen-induced rat colonic 
tumors. Gastroenterology 1996;110:1259–
1262. 
28. Muller-Decker, K., Kopp-Schneider, A., 
Marks, F., Seibert, K., and Furstenberger, G. 
Localization of prostaglandin H synthase 
isozymes in murine epidermal tumors: 
suppression of skin tumor promotion by 
inhibition of prostaglandin H synthase-2. Mol 
Carcinogen 1998;23: 36–44. 
29. Nguyen, T., Brunson, D., Crespi, C.L., 
Penman, B.W., Wishnok, J.S., and 
Tannenbaum, S.R. DNA damage and mutation 
in human cells exposed to nitric oxide in vitro. 
Proc Natl Acad Sci USA 1992;89:3030–3034. 
30. Ohshima, H., and Bartsch, H.Chronic 
infections and inflammatory processes as 
cancer risk factors: possible role of nitric 




September 2013   C. Ansah and K.B Mensah           Anticancer properties of cryptolepine 
 144 
31. Maeda, H., and Akaike, T. Nitric oxide and 
oxygen radicals in infection, inflammation, 
and cancer. Biochemistry 1998;63:854–865. 
32. Wink, D., Vodovotz, Y., Laval, J., Laval, F., 
Dewhirst, M.W., and Mitchell, J.B. The 
multifaceted roles of nitric oxide in cancer. 
Carcinogenesis 1998;19:711–721. 
33. Zhuang, J.C., Lin, C., and Wogan, G.N. 
Mutagenesis associated with nitric oxide 
production in macrophages. Proc Natl Acad 
Sci USA 1998;95: 8286–8291 
34. Salvemini, D., Seibert, K., and Marino, M.H. 
New concepts in inflammation and therapy. 
Drug News  Perspect 1996;9: 204–219. 
35. Barnes, P.J.,and Karin, M. Nuclear factor-kB, 
a pivotal transcription factor in chronic 
inflammatory disease. New Eng J Med 
1997;336: 1066-1071. 
36. Huang, S., Li, J.Y., Wu, J., Meng, L., Shou, 
C.C. Mycoplasma infections and different 
human carcinomas. World J Gastroenterol 
2001;7:266-269 
37. Posadas, I., Terencio, M.C., Guillen, I., 
Ferrandiz, M.L., Coloma, J., Paya, M., and 
Alcaraz, M.J. Co-regulation between 
cyclooxygenase-2 and inducible nitric oxide 
synthase expression in the time-course of 
murine inflammation. Naunyn-
Schmiedeberg’s Arch Pharmacol 2000;361: 
98–106.  
38. Salvemini, D., Manning, P.T., Zeifel, B.S., 
Seibert, K., Curie, M.G., Needleman, P., and 
Masferrer, J.L. Dual inhibition of nitric oxide 
and prostaglandin production contributes to 
the anti-inflammatory properties of nitric 
oxide synthase inhibitors. J Clin 
Invest.1995;96: 301–308. 
39. Tetsuka, T., Baier, L.D., and Morrison, A.R. 
Antioxidants inhibit interleukin-1-induced 
cyclooxygenase and nitric oxide synthase 
expression in rat mesangial cells. J Biol Chem  
1996;271: 11689 – 11693. 
40. Takahashi, M., Mutoh, M., Kawamori, T., 
Sugimura, T., and Wakabayashi, K. Altered 
expression of catenin, inducible nitric oxide 
synthase and cyclooxygenase-2 in 
azoxymethane-induced rat colon 
carcinogenesis. Carcinogenesis 2000 ;21: 
1319–1327. 
41. Kipp, E. and Ghosh, S. Inhibition of NF-kB 
by sodium salicylate and aspirin. Science 
1994;  265: 956-959 
42. Ghosh, S,and Karin, M. Missing pieces in the 
NF-kappaB puzzle. Cell.2002;109:S81-S96. 
43. Helbig, G., Christopherson, K.W., Bhat-
Nakshatri, P., Kumar, S., Kishimoto, H., 
Miller, K.D. Broxmeyer, H. E., and  
Nakshatri, H. NF-kappaB promotes breast 
cancer cell migration and metastasis by 
inducing the expression of the chemokine 
receptor CXCR4. J. Biol. Chem 
2003;278:21631–21638. 
44. Bamgbose, S.O., and Noamesi, B.K.Studies 
On Cryptolepine II: Inhibition of 
Carrageenan-Induced Oedema by 
Cryptolepine. Planta Med 1981;41:392–396. 
45. Olajide, O.A., Pinheiro de Oliveira, A., 
Unekwe, J., Wright, C., and Fiebich, B. 
Cryptolepis sanguinolenta (Lindl.) Schltr. root 
extract inhibits prostaglandin production in 
IL-1b stimulated SK-N-SH neuronal cells. 
Planta Med 2010;76:601. 
46. Olajide, O.A., Ajayi, A.M., and Wright, C.W. 
Anti-inflammatory Properties of Cryptolepine. 
Phytother Res.2009; 23:1421-1425. 
47. Olajide, O.A., Heiss, E.H., Schachner, D., 
Wright, C.W., Vollmar, A.M., and Dirsch, 
V.M. Synthetic cryptolepine inhibits DNA 
binding of NF-kappaB. Bioorg Med Chem 
2007; 15:43-49. 
48. Olajide, O.A., Wright, C.W., and Fiebich, 
B.L. Effects of Cryptolepis sanguinoleta root 
extract in lipopolysaccharide – stimulated 
human primary monocytes. Planta Med 
2007a; 73: 077. 
49. Thun, M.J., Namboodiri, M.M., and Heath, 
C.W. Aspirin use and reduced risk of fatal 
colon cancer. N Engl J Med.1991; 325:1593– 
1596. 
50. Kawamori, T., Rao, C.V., Seibert, K., and 
Reddy, B.S. Chemopreventive activity of 
celecoxib, a specific cyclooxygenase-2 
inhibitor, against colon carcinogenesis. 
Cancer Res.1998; 58:409 – 412. 
51. Eberhart, C.E., Coffey, R.J., Radhika, A., 
Giardiello, F.M., Ferrenbach, S., and Dubois, 
R.N. Up-regulation of cyclooxygenase 2 gene 
expression in human colorectal adenomas and 
adenocarcinomas. Gastroenterology 
1994;107: 1183–1188 
52. Kargman, S. L., O’Neill, G.P., Vickers, P.J., 
Evans, J.F., Mancini, J.A., and Jothy, S. A. 
Expression of prostaglandin G/H synthase-1 
and -2 protein. Cancer Res.1995;55:      2556–
2559. 
53. Sheng, H., Shao, J., Washington, M.K., and 
Dubois, R.N.Prostaglandin E2 increases 
growth and motility of colorectal carcinoma 
cells. J. Biol. Chem.2001;276: 18075–18081,  
54. Williams, C.S., Mann, M., and DuBois, R.N. 
The role of cyclooxygenases in inflammation, 
 
 
September 2013    Volume 47, Number 3  GHANA MEDICAL JOURNAL 
 145 
cancer, and development. Oncogene.1999;18: 
7908–7916. 
55. Ko, L.J., and Prives, C. p53: Puzzle and 
paradigm. Genes Dev.1996;10:1054–1072. 
56. Giaccia, A.J. and Kastan, M.B. The 
complexity of p53 modulation: Emerging 
patterns from divergent signals. Genes 
Dev.1998;12:2973–2983. 
57. Giardina, C., Boulares, H., Inan, M.S. 
NSAIDs and butyrate sensitize a human 
colorectal cancer cell line to TNF and Fas 
ligation: the role of reactive oxygen species. 
Biochim Biophys Acta 1999;1448: 425-438 
58. Deveraux,Q.L., Roy, N., Stennicke, H.R., Van 
Arsdale, T., Zhou, Q., Srinivasula, S.M., 
Alnemri, E.S., Salvesen, G.S., Reed, J.C. IAPs 
block apoptotic events induced by caspase-8 
and cytochrome c by direct inhibition of 
distinct caspases. EMBO J 1998;17: 2215–
2223 
59. Wang, C.Y., Mayo, M.W., Korneluk, R.G., 
Goeddel, D.V., Baldwin, A.S. Jr. NF-kappaB 
antiapoptosis: induction of TRAF1 and 
TRAF2 and c-IAP1 and c-IAP2 to suppress 
caspase-8 activation. Science 1998;281:1680–
1683 
60. Takahashi, R., Deveraux, Q., Tamm, I., 
Welsh, K., Assa-Munt, N., Salvesen, G.S., 
Reed, J.C. A single BIR domain of XIAP 
sufficient for inhibiting caspases. J Biol Chem 
1998;273:7787–7790 
61. Lee, J.U., Hosotani, R., Wada, M., Doi, R., 
Kosiba, T., Fujimoto, K., Miyamoto, Y., 
Tsuji, S., Nakajima, S., Nishimura, Y., 
Imamura, M. Role of Bcl-2 family proteins 
(Bax, Bcl-2 and Bcl-X) on cellular 
susceptibility to radiation in pancreatic cancer 
cells. Eur J Cancer 1999; 35:1374–1380 
62. Chen, Q.M., and Tu, V.C. Apoptosis and heart 
failure: mechanisms and therapeutic 
implications. Am J Cardiovasc Drugs 
2002;2:43–57 
63. Wu,Y.L., Sun, B., Zhang, X.J., Wang, S.N., 
He, H.Y., Qiao, M.M., Zhong, J.,Xu, J.Y. 
Growth inhibition and apoptosis induction of 
Sulindac on human gastric cancer cells. World 
J Gastroenterol.2001;7:796-800 
64. Bash, J., Zong, W.X., and Gelinas,C. Molc-
Rel arrests the proliferation of HeLa cells and 
affects critical regulators of the G1/S-phase 
transition. Mol. Cell. Biol. 1997;17: 6526–
6536. 
65. Perkins, N.D., Felzien, L.K., Betts, J.C., 
Leung, K., Beach, D.H., and Nabel, G.J. 
Regulation of NF-κB by Cyclin-Dependent 
Kinases Associated with the p300 Coactivator. 
Science 1997;275:523–527 
66. Karin, M.,and Lin, A. NF-kappaB at the 
crossroads of life and death. Nat. Immunol. 
2002;  3:221-227.  
67. Karin, M., Luo, J., and Kamata, H. IKK/NF-
κB signaling: balancing life and death – a new 
approach to cancer therapy. J Clin 
Invest.2005;115(10):2625–2632 
68. Yu, Q., Geng, Y., and Sicinski, P. Specific 
protection against breast cancers by cyclin D1 
ablation. Nature.2001;411:1017–1021 
69. Mensah K.B. Reproductive and 
developmental toxicity of the aqueous root 
extract of the antimalarial herbal Cryptolepis 
sanguinolenta (LINDL.) SCHLTR  
(Periplocaceae) in experimental animals. (PhD 
Thesis 2011)  
70. Marker, P.C., Donjacour, A.A., Dahiya, R., 
Cunha, G.R. Hormonal, cellular, and 
molecular control of prostatic development. 
Dev. Biol. 2003; 253, 165–174 
71. Nandeesha, H. Benign prostatic hyperplasia: 
dietary and metabolic risk factors. Int. Urol. 
Nephrol. 2008;40:649–656. 
72. Nandeesha, H., Koner, B.C., Dorairajan, L.N., 
Sen, S.K. Hyperinsulinemia and dyslipidemia 
in non-diabetic benign prostatic hyperplasia. 
Clin. Chim. Acta 2006;370:89–93. 
73. Parsons, J.K., Bergstrom, J., and Barrett-
Connor, E. Lipids, lipoproteins and the risk of 
benign prostatic hyperplasia in community-
dwelling men. BJU Int. 2008;101: 313–318. 
74. Parsons, J.K., Sarma, A.V., McVary, K., Wei, 
J.T. Obesity and benign prostatic hyperplasia: 
clinical connections, emerging etiological 
paradigms and future directions. J.Urol.2009; 
182:S27–S31. 
75. Vikram, A., Jena G,and Ramarao, P. Insulin-
resistance and benign prostatic hyperplasia: 
The connection. Eur J Pharmacol 
2010;641:75–81. 
76. Peehl, D.M., Cohen, P., Rosenfeld, R.G.The 
insulin-like growth factor system in the 
prostate. World J. Urol. 1995;13:306–311. 
77. Lucia, M.S., Lambert, J.R.Growth factors in 
benign prostatic hyperplasia: basic science 
implications. Curr. Urol. Rep. 2008;9:272–
278. 
78. Ikeda, K., Wada, Y., Foster Jr., H.E., Wang, 
Z., Weiss, R.M., Latifpour, J. Experimental 
diabetes-induced regression of the rat prostate 
is associated with an increased expression of 




September 2013   C. Ansah and K.B Mensah           Anticancer properties of cryptolepine 
 146 
79. Riccardi, G., Giacco, R., Rivellese, A.A. 
Dietary fat, insulin sensitivity and the 
metabolic syndrome. Clin. Nutr. 2004; 
23:447–456. 
80. Li, P.J., Zhang, X.H., Guo, L.J., Na, Y.Q. 
Correlation of benign prostatic hyperplasia 
with hyperlipemia. Zhonghua Wai Ke Za Zhi 
2005;43:387–389 
81. 81. Luo, J., Fort, D.M., Carlson, T.J., 
Noemesi, B.K., Nii-Amon-Kotei, D., King, 
S.R., Tsai, J., Quan, J., Hobensack, C., 
Lapresca, P., et al.  Cryptolepis 
sanguinolenta:an ethnobotanical approach to 
drug discovery and the isolation of a 
potentially useful new antihyperglycaemic 
agent. Diabet Med   1998 15:  367-374. 
82. Werner, H., and LeRoith, D. The role of the 
insulin-growth factor system in human cancer. 
Adv. Cancer Res.1996;68: 183–222 
83. Humbel, R. E. Insulin-like growth factors I 
and II. Eur. J. Biochem. 1990;190: 445–462. 
84. Tanno, S., Tanno, S., Mitsuuchi, Y., 
Altomare, D.A., Xiao, G.H., and Testa, 
J.R.Akt activation up-regulates insulin-like 
growth factor I receptor expression and 
promotes invasiveness of human pancreatic 
cancer cells. Cancer Res.2001;61: 589–59. 
85. Matias-Guiu, Dolcet, X.,  Llobet, D.,  Pallares, 
J.  NF-kB in development and progression of 
human cancer. Virchows Arch. 2005;446: 
475–482 
86. Panka, D.J., Mano, T., Suhara, T., Walsh, K., 
Mier, J.W. Phosphatidylinositol 3-kinase/Akt 
activity regulates c-FLIP expression in tumor 
cells. J Biol Chem. 2001; 276:6893–6896 
87. Bullani, R.R., Huard, B., Viard-Leveugle, I., 
Byers, H.R., Irmler, M., Saurat, J.H, Tschopp, 
J., French, L.E.Selective expression of FLIP 
in malignant melanocytic skin lesions. J Invest 
Dermatol 2001;117:360–364 
88. Olsson, A, Diaz, T., Aguilar-Santelises, M., 
Osterborg, A., Celsing, F., Jondal, M., Osorio, 
L.M. Sensitization to TRAIL induced 
apoptosis and modulation of FLICE-inhibitory 
protein in B chronic lymphocytic leukemia by 
actinomycin D. Leukemia 2001;15:1868–18 
89. Shen, H.M. and Tergaonkar,V. NFkappaB 
signaling in carcinogenesis and as a potential 
molecular target for cancer therapy. Apoptosis 
2009;14:348–363. 
90. Cimanga, K., De Bruyne, T., Pieters, L., 
Vlietinck, A.J., Turger, C.A. In vitro and in 
vivo antiplasmodial activity of cryptolepine 
and related alkaloids from Cryptolepis 
sanguinolenta. J Nat Prod 1997; 60:688-691 
91. Kirby, G.C., Paine, A., Warhurst, D.C., 
Noamesi, B.K., Phillipson, J.D. In vitro and in 
vivo antimalarial activity of cryptolepine, a 
plant-derived indoloquinoline. Phytother Res 
1995;  9: 359-363 
92. Baguley, B.C., and Ferguson, L.R. (1998. 
Mutagenic properties of topoisomerase-
targeted drugs. Biochim Biophys Acta 1998; 
1400: 213–222. 
93. Fortune, J.M., and Osheroff, N.  
Topoisomerase II as a target for anticancer 
drugs: when enzymes stop being nice,. Prog 
Nucleic Acid Res Mol Biol 2000; 64: 221–253. 
94. Kaufmann, S.H. Cell death induced by 
topoisomerase-targeted drugs: more questions 
than answers. Biochim Biophys Acta 1998; 
1400: 195–211. 
95. Wilstermann, A.M., and Osheroff, N.  
Stabilization of eukaryotic topoisomerase II–
DNA cleavage complexes. Curr Top 
MedChem 2003; 3: 1349–1364. 
96. Walker, J.V., and Nitiss, J.L.  DNA 
topoisomerase II as a target for cancer 
chemotherapy. Cancer Invest 2002; 20: 570– 
589. 
97. Nguyen, T., Brunson, D., Crespi, C L., 
Penman, B W., Wishnok, J. S,. Tannenbaum, 
S. R. DNA damage and mutation in human 
cells exposed to nitric oxide in vitro. Proc. 
Natl. Acad. Sci. U.S.A.1992; 89: 3030–3034 
98. Ohshima, H., & Bartsch, H. Chronic 
infections and inflammatory processes as 
cancer risk factors: possible role of nitric 
oxide in carcinogenesis, Mutat. Res.1994; 305 
: 253–264 
99. Wink, D., Vodovotz, Y., Laval, J., Laval, F., 
Dewhirst, M. W., Mitchell, J. B. The 
multifaceted roles of nitric oxide in cancer, 
Carcinogenesis 1998;19: 711–721 
100. Zhuang, J. C., Lin, C., Wogan, G. N. 
Mutagenesis associated with nitric oxide 
production in macrophages, Proc. Natl. Acad. 
Sci. U.S.A.1998;95 : 8286–8291. 
101. Maeda, H., & Akaike, T. Nitric oxide and 
oxygen radicals in infection, inflammation, 
and cancer, Biochemistry 1998; 63 :854–865 
102. Bugyei, K.A., Boye, G.L., and.Addy, M.E. 
Clinical efficacy of a tea-bag formulation of 
Cryptolepis sanguinolenta root in the 
treatment of acute uncomplicated falciparum 
malaria. Gh. Med. J. 2010;1(44): 3-9 
103. Ansah, C., Mfoafo, E.A., Woode, E., Opoku-
Okrah, C., Owiredu, W.K.B.A, and Duwiejua, 
M. Toxicological evaluation of the 
antimalarialherb Cryptolepis sanguinolenta in 
 
 
September 2013    Volume 47, Number 3  GHANA MEDICAL JOURNAL 
 147 
rodents. J. Pharmacol. Toxicol.2008;3: 335-
343 
104. Komhoff, M., Grone, H.J., Klein, T., 
Seyberth, H.W., and Nusing, R.M. 
Localization of cyclooxgenase-1 and 2 in 
adult and fetal human kidney: implication for 
renal function,. Am J Physiol 1997. 
105. Perazella, M.A.COX-2 inhibitors and the 
kidney. Hospital Practice 2001;3,43–56. 
106. Williams, C.S., Mann, M., and DuBois, R.N. 
The role of cyclooxygenases in inflammation, 
cancer, and development. 
Oncogene.1999;18:7908–7916. 
107. Rossat, J., Maillard, M., Nussberger, J.,  
Nrunner, H.R., and Burnier, M. Renal effects 
of selective cyclooxgenase-2 inhibitor in 
normotensive salt-depleted subjects. Clin 
Pharmacol Ther 1999;66: 76–84✪ 
 
 
 
